Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 outlined. Insights into payor access and reimbursement strategies discussed.
Eli Lilly and Company (NYSE:LLY) is set to report first-quarter earnings on Tuesday, April 30. Analysts expect the Indianapolis, Indiana-based company’s quarterly earnings to be $2.46 per share, up from $1.62 per share in the year-ago period. Eli Lilly is projected to post revenue of $8.92 billion, compared to $6.96 billion in the year-earlier quarter, according to data from Benzinga Pro. Fresh off its acquisition of a manufacturing facility from Nexus Pharmaceuticals, some investors may be eyei
Giant Pharmaceutical Manufacturer Buys Pleasant Prairie Company wlip.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wlip.com Daily Mail and Mail on Sunday newspapers.